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Abstract.  Two new members (Sarla and Sarlb) of the 
SAR1 gene family have been identified in mammalian 
cells.  Using immunoelectron microscopy, Sarl  was 
found to be restricted to the transitional  region where 
the protein was enriched 20-40-fold in vesicular car- 
riers mediating ER to Golgi traffic.  Biochemical anal- 
ysis revealed that Sarl  was essential for an early step 
in vesicle budding.  A  Sad-specific antibody potently 
inhibited export of vesicular stomatitis virus glycopro- 
tein (VSV-G)  from the ER in vitro. Consistent with 
the role of guanine nucleotide exchange in Sarl  func- 
tion,  a trans-dominant mutant (Sarla[T39N])  with a 
preferential affinity for GDP also strongly inhibited 
vesicle budding from the ER.  In contrast,  Sarl  was 
not found to be required for the transport of VSV-G 
between sequential Golgi compartments,  suggesting 
that components active in formation of vesicular car- 
riers mediating ER to Golgi traffic may differ, at least 
in part,  from those involved in intra-Golgi transport. 
The requirement for novel components at different 
stages of the secretory pathway may reflect the re- 
cently recognized differences in protein transport be- 
tween the Golgi stacks as opposed to the selective 
sorting and concentration of protein during export 
from the ER. 
M 
ULTIPLE GTPases are now recognized to regulate 
vesicular traffic between compartments  of the exo- 
cytic pathway. They include members of the Rab/ 
YPT/SEC4, Sarl, Arf, and G~a, gene families (reviewed in 
Goud and McCaffrey,  1991; Barr et al.,  1992; Bomsel and 
Mostov,  1992; Pfeffer, 1992; Zerial and Stenmark,  1993). 
These proteins are proposed to serve as molecular switches 
which monitor and coordinate sequential  interactions  be- 
tween the components of transport machinery required for 
a single round of budding,  targeting,  and fusion of transport 
vesicles.  Members of the Sarl family are evolutionarily  dis- 
tant from both the Rab/YPT1/SEC4 family (<30 % identity), 
but show slight homology to the Arf family. Only one mem- 
ber has been identified to date in Saccharomyces cerevisiae 
(Nakano and Muramatsu, 1989), although homologues have 
been found in Schizosaccharomyces pombe and Arabidopsis 
thaliana (d'Enfert  et al.,  1992). In yeast, Sarlp plays a key 
role in the export of protein from the ER (Nishikawa  and 
Nakano,  1991; Oka et al., 1991; Salama et al., 1993). Sarlp 
function  requires Secl2p (a Sarlp-specific  guanine  nucleo- 
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tide  exchange  factor  [GEF] ~)  (Barlowe  and  Schekman, 
1993) and Sec23p (a Sarlp-specific  GTPase activating pro- 
tein [GAP]) (Yoshihisa et al., 1993). Recently, these compo- 
nents in addition  to three other soluble proteins have been 
purified  to homogeneity and demonstrated to be sufficient 
for vesicle budding from the ER in yeast (Nakano  et al., 
1988;  Hicke and  Schekman,  1989;  d'Enfert  et al.,  1991; 
Hicke et al., 1992; Barlowe et al., 1993; Pryer et al., 1993; 
Salama et al., 1993; Yoshihisa et al., 1993). In mammalian 
cells, Sarl function has been indirectly linked to the require- 
ment for/~-COP in vesicle budding from the ER (Peter et al., 
1993). The possible involvement of Sarlp in other steps of 
the secretory pathway has not been investigated. 
To begin to understand  the similarities  and differences be- 
tween export from the ER and vesicular traffic through the 
Golgi apparatus  in mammalian  cells, we have identified two 
closely  related  mammalian  homologues  of  yeast  Sarlp 
(designated Sarla and Sarlb). We find that Sarl, unlike either 
Art  (Orci et al.,  1991b, 1993; Serafini et al.,  1991; Kahn 
et al., 1992; Taylor et al., 1992; Palmer et al., 1993) or Rabl 
(Davidson and Balch, 1993; Nuoffer et al., 1994; Pind et al., 
1.  Abbreviations  used in  this paper:  endo H,  endoglycosidase  H; GAP, 
GTPase activating protein; GEE guanine nucleotide exchange factor; RER, 
rough endoplasmic reticulum; VSV-G, vesicular stomatitis virus glycopro- 
tein; GTP),S,  guanosine-5'-O-(3-thiotriphosphate). 
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compartments.  These  results  provide  novel  evidence  that 
small  GTPases  (and  their  associated  effectors)  regulating 
vesicle budding from the ER and from compartments of the 
Golgi may, in part, be distinct. This could reflect differences 
in the need for these two organdies to recruit cargo to vesic- 
ular carriers  (Balch et al.,  1994;  Pind et al.,  1994). 
Materials and Methods 
cDNA Cloning 
Degenerate  oligonucleotide  mixtures corresponding to regions  of identity 
among the reported SAR1 protein sequences of Saccharomyces  cerevisiae, 
Schizosaccharomyces  pombe, and Arabidopsis  thaliana  were used to am- 
plify Sarl eDNA from a CHO eDNA library (Uni-ZAP XR; Stratagene, 
La Jolla, CA) by two stage PCR. The primers used for the first round of 
amplification  were  GG(ATG-C)(TC)TIGA(TC)AA(TC)GC(AGTC)GG 
(codons  Gly32-Gly  37, sense)  and (GC)(AT)(AG)CACAT(AG)AA(AGTC)- 
AC(TC)TC (codons Glu174-Ser  179, antisense).  The same antisense primer 
and  GA(TC)AA(TC)GC(AGTC)GG(AGTC)AA(AG)AC  (codons  Asp  34- 
Thr  4°, sense) were used for the second round of amplification.  All nucleo- 
tides in parentheses were included at that position. The amplification reac- 
tions were performed for five cycles with a denaturing temperature of 940C 
for 1 rain, annealing at 470C for 1 rain, and elongation at 720C for 2 min, 
followed by an additional 25 cycles with a denaturing temperature of 94°C 
for 1 rain, annealing at 55°C for 1 rain, and elongation at 720C for 2 min. 
For the second round of amplification,  the first round reaction was diluted 
1O,000-fold and used as the template.  The O.4-kb product of the second 
round amplification  was subcloned into a plasmid, pBluescript II (Strata° 
gene), sequenced,  and used as a probe for screening a CHO eDNA library 
constructed with the bacteriophage k vector (Uni-ZAP XR; Stratagene). 
Hybridizations were done for 24 h at 65 oC in 5 x  SSPE (1 x SSPE -- 0.15 M 
NaC1, 1 mM EDTA,  10 mM NaI-i2PO4, pH 7.4), 5x Denhardt's solution, 
0.5% SDS, and 100/~g/ml herring sperm DNA. A final wash was performed 
in lx SSPE, 0.1% SDS at 65°C for 1 h. Eleven positive h clones were iso- 
lated, and the DNA inserts with the vector sequence carried by the k clones 
were rescued by in vivo excision according to the manufacturer's procedure, 
analyzed by restriction enzyme digestion and partial sequencing,  and then 
restricted to two sets of  overlapping cDNAs. Both strands of each of the lon- 
gest cDNAs termed Sarla and Sarlb DNA,  respectively,  were  fully  se- 
quenced with Sequence (United States Biochemical Corp., Cleveland, OH) 
using walking primers.  Plasmids, pBluescript H carrying Sarla and Sarlb 
cDNA, were termed pBluescript-Sarla  and pBluescript-Sarlb,  respectively. 
Expression of  His-tagged Sarla, Sarlb, and Sarla- 
(T39N) Proteins in Escherichia coli 
The coding region of Sarla, Sarlb, and Sarla(T39N)  (see below)  cDNAs 
were engineered by PCR to add a BamHI site and a sequence (ATCGAGGG- 
TAGA) corresponding to a factor Xa cleavage site immediately upstream of 
the first ATG and to add a HindHI site immediately  downstream of the ter- 
mination codon. The PCR products were digested with BamHI and HindRI 
and cloned into the pQE9 vector (QIAGEN  Inc., Cbatsworth,  CA).  The 
resulting plasmids, termed pQE-Sarla, pQE-Sarlb, and pQE-SARIa-T39N, 
respectively, were introduced into Escherichia coli (MI5 harboring plasmid 
pREP4; QIAGEN).  The transforraants were grown to a density of A600 ffi 
0.9 in Super medium (25 g bacto-tryptone, 15 g yeast extract, and 5 g NaC1 
per liter with 100/zg/ml arnpicillin and 500/~g/ml kanamycin) at 370C and 
further cultivated  for 2  h  in the presence of 2  mM isopropyl-thio-/~-D- 
galactoside  at 37°C to induce the recombinant proteins. 
Purification of  His,-tagged Sarl Proteins 
Method 1. Hiss-tagged  Sarla protein purified  by this procedure was used 
as an antigen to produce polyclonai antibody. E. coli transformants express- 
ing Hiss-tagged Sarla protein were suspended in sonication buffer (50 mM 
Na-phosphate [pH  8.0], 0.3  M NaCI)  containing 1 mg/ml lysozyme,  in- 
cubated on ice for 10 min, and then disrupted by sonication.  The lysate was 
clarified by centrifugation at 10,000 g for 30 rain, and the supernatant was 
loaded  on a nickel-nitrotriacefic  acid (Ni-NTA)-agarose (QIAGEN  Inc.) 
column (8-ml bed volume) previously equilibrated with sonication buffer. 
The resin was washed with sonication buffer containing 20 mM imidazole 
and then Hiss-tagged  Sarla protein was eluted with a  100-ml imidazole 
gradient (20-500 mM) in sonication buffer. Hiss-tagged  Sarla protein was 
pooled and precipitated with 60% saturated ammonium sulfate, dissolved 
in PBS, and then dialyzed  against PBS. 
Method 2. Hiss-tagged  Sarla proteins purified by this procedure were 
used for cell-free transport assays. E.  coli transformants expressing  Hiss- 
tagged wild-type  Sarla and the T39N mutant were suspended  in buffer A 
(10% glycerol,  150 mM KCI, 5 mM magnesium acetate, 0.1 mM DTT, 20 
mM Hepes-KOH,  pH 7.0) containing 1 mM PMSF, disrupted in a French 
press, and then the lysate was clarified by centrifugation at 10,000 g for 30 
rain. The supernatant was loaded on a Ni-NTA-agarose  column (1-ml bed 
volume) previously  equilibrated with buffer A and washed with buffer A 
containing 20 mM imidazole.  The Hiss-tagged  protein was  eluted with 
7 mi of buffer A  containing 100 mM imidazole,  precipitated with 60% 
saturated ammonium sulfate,  dissolved  in buffer A, and dialyzed  against 
buffer A. 
Preparation of  Antibody to Sarla Protein 
A rabbit was injected with 1 mg purified  Hiss-tagged  Sarla protein emul- 
sifted in Freund's complete adjuvant,  followed with 1 rag purified Hiss- 
tagged Sarla protein emulsified in Freund's incomplete adjuvant every three 
weeks to boost the immune response. Antibody to Sarla protein was aitinity- 
purified  as described (Harlow  and Lane,  1988) by adsorption to Hiss- 
tagged Sarla protein conjugated to AminoLink  ° coupling gel (Pierce Chem. 
Co., Rockford, IL) according to the manufacturer's procedure,  precipitated 
with 60% saturated ammonium sulfate, dissolved in 10 mM MOPS-KOH 
(pH 7.5) and 150 mM KC1, and dialyzed  against the same buffer. 
Construction of  Sarla Mutants 
The T39N and N134I mutations were introduced into the wild-type Sarla 
sequence carried by pBluescript-Sarla, using site-directed  mutngenesis as 
described (Higuchi et ai., 1988). The resulting plasmids were termed pBlue- 
script-Sarla-T39N  and pBluescript-Sarla-N134I,  respectively. For transieni 
expression of wild-type and mutant Sarla proteins in HeLa cells, the coding 
regions of wild-type and mutant Sarla cDNAs were engineered by PCR to 
add a NdeI site immediately  upstream of the first ATG and a BamI-II site 
immediately  downstream of the termination codon,  using pBluescript- 
Sarla, pBluescript-Sarla-T39N,  and pBluescript-Sarla-N134I  as templates. 
The PCR products were digested with NdeI and BamHI, and subcloned into 
these restriction enzyme sites of the pET3a vector (Novagen, Inc., Madi- 
son, WI) for expression from the T7 promoter.  All mutant and wild-type 
Sarl sequences  engineered by PCR were verified by DNA sequencing. 
Immunoblot Analysis 
Proteins were fractionated by  12.5%  polyacrylamide  SDS-PAGE under 
reducing conditions (Laemmii, 1970) and electroblotted on to nitrocellu- 
lose in 25 mM Tris,  192 mM glycine,  and 20% methanol at 22 V/cm for 
1 h.  Sarl  proteins  were  detected  using the  affinity-purified  anti-Sarla 
antibody (25 ng/ml) and peroxidase-conjugated  anti-rabbit IgG (diluted 
1:1,000). Peroxidase labeling was detected by chemiluminescence using the 
ECL reagent  (Amersham Corp., Arlington Heights,  IL) according to the 
manufacturer's  recommendations. 
Cis- to Mediai-Goigi Transport  Assay 
The preparation of assay components and standard incubation conditions 
were as described previously  (Balch et al.,  1984; Malhotra et al.,  1988). 
Reactions (50 ~d) contained 25 mM Hepes (pH 7.0), 25 mM KCI, 2.5 mM 
magnesium acetate, 5 mM creatine phosphate, 0.25 mM UTP, 0.05 mM 
ATP, 8 IU/ml creatine kinase, 8/~M palmitoyl  CoA, 0.4/tM UDP-3H-N  - 
acetylglucosamine  ([3H]GlcNac), bovine brain cytosol (5 t~l), donor stacks 
(5/~1), and acceptor stacks (5/~1). To test the effect of anti-Sarla antibody, 
the reactions were incubated on ice for 1 h to promote antibody-antigen 
binding and then incubated at 37°C for assay. 
Transport in Semi-intact and PermeabUized  Cells 
NRK cells were infected with the ts045 strain of vesicular stomatitus virus 
(VSV) and pulse labeled with 10/tCi Trans [3sS]-label at the restrictive 
temperature (39.5°C) to accumulate the VSV-glycoprotein (VSV-G) mutant 
in the ER. The cells were then perforated by the swelling and scraping pro- 
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Balch, 1993). Transport between the ER and the cis/medial-Golgi compart- 
ments was measured biochemically by following the appearance of endogly- 
cosidase H (endo H)-resistant forms of VSV-G upon incubation at the per- 
missive temperature (32°C) in the presence of cytosol and ATP as described 
previously (Plutner et al., 1992; Davidson and Balch, 1993). Briefly, trans- 
port reactions were performed in a final volume of  40/~1 in a buffer contain- 
ing 25 mM Hepes-KOH  (pH 7.2), 75 mM KOAc, 2.5 mM MgOAc, 5 mM 
EGTA,  1.8 mM CaC12, 1 mM N-acetyl glucosamine, an ATP regenerating 
system (1 mM ATP, 5 mM creafine phosphate, and 0.2 IU rabbit muscle 
creatine pbosphokinase,  final concentrations), 2-6  /al rat liver cytosol 
(20-60 ~g/ml protein in 35 rnM Hepes-KOH  [pH 7.2],  125 mM KOAc), 
and 5 ~,1 semi-intact cells (25-30/zg protein or 1-2 x  10  s cells in 50 mM 
Hepes-KOH  [pH 7.2],  90 mM KOAc). The reactions were incubated at 
32°C for 2 h, membranes collected by centrifugation, solubilized,  digested 
with endo H, and processed for SDS-PAGE and fluorography  as described 
(Balch et al., 1986; Plumer et al., 1992; Davidson and Balch, 1993). Auto- 
radiographs were quantitated by a PhosphorImager (Molecular Dynamics, 
Palo Alto,  CA). 
For morphological analysis of transport, the cells were permeabilized 
with digitonin as described (Plntner et al.,  1992).  Incubation conditions 
were as outlined above, except that the reactions were performed in a final 
volume of 200 ~l. The cells were processed for indirect immunofluores- 
cence as described previously (Balch, 1990; Plutner et al., 1992). An anti- 
body specific for ManH (Velaseo et al., 1993) was generously provided by 
M.G. Farquhar (Division of Cellular and Molecular Medicine, University 
of California, San Diego,  CA). 
Transient Expression and Analysis of Transport 
in HeLa Cells 
Experimental procedures for the transient expression of pET-Sarl  con- 
structs in HeLa cells were essentially as described previously  (Tisdale et 
al., 1992). Briefly, cells infected with the T7 RNA polymerasc-recombinant 
vaccinia virus vTF7-3 (Fuerst et al.,  1986) were eotransfected  with 1 Izg 
pAR-G (encoding VSV-G), and 2.5 ~g of the appropriate pET-Sarl  con- 
structs using the Transfect ACE  TM (GIBCO BRL, Gaithersburg, MD) pro- 
cedure.  After pulse labeling the cells for 10 rain with 20/~Ci Trans [3~S]- 
label (1,192 Ci/mmol; ICN Biomedicals Inc., Irvine, CA) followed by a 
60-rain chase, transport between the ER and the cislmedial-Golgi compart- 
ments was assessed biochemically by monitoring the processing of VSV-G 
for endo H-sensitive to endo H-resistant forms as described (Tisdale et al., 
1992; Davidson and Balch, 1993). For morphological analysis of transport, 
cells cotransfected with pAR-tsO45-G  (encoding the temperature-sensitive 
tsO45 mutant of  VSV-G [Lafay,  1974])  and  appropriate  pET-Sarl  constructs 
were  incubated  at  the  restrictive  temperature  (39.5°C)  for  4 h to  accumulate 
the protein  in the ER. Transport  was initiated  by shifting  the cells  to the 
permissive  temperature  (32°C).  After  a 2-h  incubation  the  cells  were  pro- 
cessed  for  indirect  immunofluorescence as  described  (Tisdale  et  al.,  1992). 
Immunocytochemistry 
Indirect Immunofluorescence. Monolayer cultures of NRK cells,  CHO- 
cells, and islet cells of neonatal rat pancreas were fixed with Bouin's fluid. 
Cells were permeabilized by dehydration and rehydration with ethanol and 
processed by the immunofluorescence  technique.  Affinity-purified  rabbit 
antibodies raised against bacterially expressed His6-tagged Sarla protein 
(40-80 ~g IgG/ml) were applied for 2 h at room temperature in a moist 
chamber followed by washing with PBS and exposure  to FITC-conjugated 
goat anti-rabbit IgG. Cells were washed with PBS and counterstained with 
0.03 % Evans blue before examination with a confocal fluorescence  micro- 
scope. As a control, preimmune IgG was applied instead of the primary an- 
tibody. 
lmmunoelectronmicroscopy. Fragments of pancreatic tissue freshly re- 
moved from normal adult rats were fixed with 1% gintaraldefiyde in 0.1 M 
sodium phosphate (pH 7.4). After 1 h of fixation, the tissue was washed with 
buffer, infiltrated with sucrose,  and processed for cryoultramicrotomy  as 
described by Tokuyasu (1980). Islets of Langerhans isolated from rat pan- 
cw,  as by collagenase  digestion were similarly fixed  and processed.  Im- 
munolocalization of Sarl on cryosections  was carried out by the protein 
A-gold technique. Thin sections were incubated at room temperature with 
affinity-porified  anti-Sarl antibodies.  Sections  were subsequently  washed 
with PBS, exposed  to the protein A-gold solution (gold particles size  10 
rim),  and absorption stained with uranyl acetate according  to Tokuyasu 
(1986). 
Quantitative Evaluation. For qnantitation  of the immunolabeling,  fields 
of insulin  cells showing Golgi regions and associated transitional areas were 
photographed and printed at a calibrated magnification of 78,864 ×. Transi- 
tional areas were defined as the areas of the cytoplasm bordered by transi- 
tional elements of the ER and cistemae of the Golgi apparatus, and containing 
the transfer vesicles.  For the quantitative evaluation of Sarl immunolabel- 
ing, the transitional areas or the vesicles were delimited with an electronic 
pen and the number of gold particles in this area was recorded with the same 
pen connected to a microprocessor programmed to calculate the number of 
gold particles per unit area (~,m2). Gold particles were also quantitated on 
RER and Golgi stacks.  On the latter, a line was traced in the middle of the 
stack: the half proximal to the transitional area was quantitated as the cis- 
Golgi,  the half distal to the transitional area as trans-Golgi. 
1 
CHO  (sarla)  MSFIFDWIYS  GF$SVLQFLG  LYKKTGKLVF  LGLDNAGKTT 
CHO  (sarlb)  *********E  **N*******  ****S*****  *****~**** 
S.  cerevisiae  MAGWDIFG  WFRDVLASLG  LWNKHGKLLF  LGLDNAGKTT 
S.  pombe  MFIIN WFYDALAMLG  LVNKHAKMLF  LGLDNAGKTT 
A.  thaliana  MFLFD  WFYGILASLG  LWQKEAKILF  LGLDNAGKTT 
Consensus  F  L  LG  L  K  K  F  LGLDNAGKTT 
61 
CHO  (sarla)  SEELTIAGMT  FTTFDLGGHI 
CHO  (sarlb)  **********  *********E 
S.  cerevisiae  SEELAIGNIK  FTTFDLGGHI 
S.  pombe  SEELAIGNVR  FTTFDLGGHQ 
A.  thaliana  SEELSIGKIK  FKAFDLGGHQ 
Consensus  SEEL  F  FDLGGH 
121 
CHO  (sarla)  DETIANVPIL  ILGNKIDRPE 
CHC  (sarlb)  ****S*****  ********TD 
S.  cerevisiae  IAELKDVPFV  ILGNKIDAPN 
S.  pombe  MEELARVPFL  ILGNKIDAPG 
A.  thaliana  DEALATVPFL  ILGNKIDIPY 
Consensus  VP  ILGNKID 
181 
CHO  (sarla)  LKRQGYGEGF  RWMAQYID 
CHO  (sarlb)  **********  **LS**** 
S.  cerevisiae  VMRNGYLEAF  QWLSQYI 
S.  pombe  VLRQGYGEGF  KWLAQYV 
A.  thaliana  VRKMGYGEGF  KWLSQYIN 
Consensus  GY E  F  W  QY 
6O 
LLHMLKDDRL  GQHVPTLHPT 
LLHMLKNDRL  ATLQPTWHPT 
LLHMLKNDRL  AVMQPTLHPT 
LLHMLKDERL  VQHQPTQHPT 
LLHMLK  RL  PT  HPT 
QARRVWKNYL  PAINGIVFLV 
**********  ********** 
QARRLWKDYF  PEVNGIVFLV 
QARRLWRDYF  PEVNGIVYLV 
IARRVWKDYY  AKVDAVVYLV 
ARR W  Y  V  LV 
120 
DCADHERLLE  SKEELDSLMT 
*****S**M*  **V**NA*'* 
DAADPERFDE  ARVELDALFN 
DCCDFERLSE  SKAELDALLA 
DAYDKERFAE  SKRELDALLS 
D  D  R  E  EL  L 
180 
AISEERLREM  FGLYGQTTGK  GSVSLKELNA  RPLEVFMCSV 
*****K***I  **********  *N********  *M******** 
AVSEAELRSA  LGLLN.TTG .... SQRIEGQ  RPVEVFMCSV 
AISEDELKAA  LGLYQ.TTGK  G.VSKPVPGI  RPIEVFMCSV 
AASEDELRYH  LGLTNFTTGK  GKVTLGDSGV  RPLEVFMCSI 
A  SE  L  GL  TTG  V  R  EVFMC$ 
Figure I. Comparison of protein 
sequences of the members of the 
SARI family (single letter amino 
acid code). The ORFs of the cor- 
responding  eDNA  clones  were 
translated  and  compared  by 
BESTFIT  alignment  (Devereux 
et  al.,  1984).  The  underlined 
areas  indicate conserved  GTP- 
binding  domains  found  in  all 
members of the ras-superfamily 
(Bourne  et al., 1991;  Witting- 
hofer and Pal, 199D.  Asterisks 
denote identity  between the CHO 
Sarla and Sarlb sequences. Con- 
sensus  (identical) amino  acids 
found  in  all  of  the  members of  the 
SARI  family are shown  in the 
bottom line. 
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Isolation of  Mammalian Homologues of Yeast SARI 
Degenerate oligonucleotide mixtures corresponding to re- 
gions of homology between the  reported S.  cerevisiae, S. 
pombe,  and A.  thaliana  sequences  (d'Enfert et al.,  1992) 
were used to generate DNA fragments from a eDNA library 
of CHO cells by the polymerase chain reaction.  A  eDNA 
fragment that encoded  a  SARl-like protein was used as a 
probe to screen a CHO eDNA library. Two different eDNA 
clones were obtained, both of which encode SARl-like pro- 
teins, designated Sarla and Sarlb (Fig.  1). The mammalian 
Sarla and Sarlb cDNAs contain open reading frames of 597 
nucleotides, encoding proteins of 198 amino acids with pre- 
dicted molecular masses of 22,413  and 22,388  D,  respec- 
tively. Fig. 1 shows a comparison of the amino acid sequence 
of five Sarl proteins cloned to date. Sarla and Sarlb are 91% 
identical (Table I). They share 60-67 % identity with yeast 
and plant Sarlp (Table I), indicating that the Sarl  family is 
evolutionarily conserved. In contrast, the Sarl proteins are 
<30%  identical to other members of the Ras superfamily 
(Table I), suggesting that they play a distinct role in vesicular 
trafficking.  The  regions  which  confer homology to  other 
members of the Ras superfamily are the amino acids under- 
lined in Fig.  1.  These comprise the three highly conserved 
motifs involved in GTP binding and hydrolysis found in all 
GTP-binding  proteins  examined  to  date  (Valencia  et  al., 
1991;  Wittinghofer and Pal,  1991). 
Mammalian Sarl Is Highly Enriched on 
Vesicular Carriers Found in the Transitional Region 
of the ER 
To establish that the cDNAs isolated encoded functional Sarl 
proteins, Sarla and Sarlb cDNAs were cloned into the pQE9 
vector to produce proteins containing histidine residues at 
their  NH: termini  (Hochuli  et al.,  1988).  These proteins 
were expressed in E. coli and purified by affinity chromatog- 
raphy on nickel-nitrolotriacetic acid (Ni-TCA)-agarose (Fig. 
2, A and B).  Affinity-purified anti-Sarla antibody was pre- 
pared and its specificity examined by Western blotting. The 
polyclonal antibody recognized two prominent proteins in 
CHO lysates with molecular masses of 27 to 28 kD (Fig. 3). 
Table 1.  Percentages of Amino Acid Identities between 
SAR1,  Human ARF,  and Human RAB Proteins 
CHOa  CHOb S.c.S.p.A.t.  ARF1 ARF5 rabl rab2 rab6 
CHOa  100  91  61  67  61  30  30  22  22  23 
CHOb  100  61  65  60  29  30  22  22  25 
S.c.  100  72  64  37  34  24  17  22 
S.p.  100  67  35  35  26  19  21 
A.t.  100  34  34  24  20  20 
ARF1  100  80  25  24  19 
ARF5  100  28  21  19 
rabl  100  48  37 
rab2  100  39 
rab6  100 
Identities of each pairs of proteins were obtained by BESTFIT  program. Ab- 
breviations used are CHOA, sarla protein of CHO; CHOB, sarlb protein of 
CHO; S.c., Sarl protein  ofS. cerevisiae; S.p., Sarl protein  of S. pombe; A.t.. 
Sarl protein of A. thaliana. 
Figure 2. Expression and purification of wild-type and mutant pro- 
teins. (A) E. coil transformants harboring pQE-Sarla  (lanes 1 and 
2), pQE-Sarlb  (lanes 3 and 4), and pQE-Sarla-T39N (lanes 5 and 
6) were grown to a density of A600  =  0.9 and further cultivated 
for 2 h at 37°C in the absence (lanes 1, 3, and 5) or in the presence 
(lanes 2, 4, and 6) of 2 mM isopropyl-thio-/~-D-galactoside. Pro- 
teins of the cell lysates (30/zl culture) were fractionated by 12.5 % 
polyacrylarnide  SDS-PAGE and  stained  with  Coomassie  blue. 
Open triangles indicate the induced Sarl proteins.  (B) Wild-type 
Sarla (lane 1 ) and Sarla(T39N)  mutant (lane 2) proteins purified 
by the method 2 as described in Materials and Methods were run 
on 12.5% polyacrylamide SDS-PAGE (LaemmU, 1970) and stained 
with Coomassie blue. 
The mobilities of  these two species correspond to the slightly 
differing  mobilities  of recombinant  His-tagged  Sarla  and 
Sarlb (Fig. 3), suggesting that these two species may be the 
endogenous proteins corresponding to the eDNA clones. 
The affinity-purified anti-Sarla antibody was used to deter- 
mine the distribution of Sarl in mammalian cells. Using in- 
direct immunofluorescence, Sarl was not routinely abundant 
in  the  extensive cisternae  comprising the  bulk of the  ER 
membrane. Rather,  Sarl  was largely localized to the juxta- 
nuclear Golgi region in NRK (Fig. 4 B) and CHO cells (Fig. 
4 C). In pancreatic insulin cells (Fig. 4 A), the Sarla distribu- 
tion had a more extended reticular pattern due to the highly 
amplified secretory compartments found in these cells.  In 
general, the pattern of Sarl distribution is in part characteris- 
tic of the distribution of p53 and p58, markers for pre-Golgi 
intermediates which are abundant in the juxtanuclear Golgi 
region (Sehleifer et al.,  1982; Schweizer et al.,  1988,  1990, 
1991;  Saraste and Svensson,  1991). 
Using immunoelectron microscopy, Sarl immunogold par- 
ticles were found in rat pancreatic insulin cells to be abun- 
Figure 3. CHO cells contain two Sarl 
isoforms. 60/zg protein of CHO cell 
lysate (lane/) and lysates (5 ng pro- 
tein)  of E.  coil transformants  ex- 
pressing  His6-tagged Sarla  (lane 2) 
and Hiss-tagged Sarlb (lane 3) were 
separated by 12.5 % polyacrylamide 
SDS-PAGE and probed on Western 
blot with  the  affinity-purified anti- 
Sarla antibody as described in Mate- 
rials and Methods. 
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cence microscopy of insulin-secreting pancreatic endocrine cells 
(A), NRK cells (B) and CHO cells (C) stained with the affinity- 
purified anti-Sarl  IgG. A juxtanuclear  fluorescent pattern corre- 
sponding to the location of the Golgi region is seen in the three cell 
types. In insulin cells, it has an extended reticular pattern due to 
the highly amplified secretory compartment. Bar, 20/~m. 
dant on smooth transitional elements of the ER and on vesic- 
ular  profiles  in  the  proximal  Golgi  cisternae  facing  the 
transitional region (Fig. 5, A and B). The transitional region 
contained clusters of immunolabeled 40-60-nm vesicles, to- 
gether with clusters of unlabeled vesicles.  Sarl  was prin- 
cipally detected as a membrane-associated form (Table II). 
Quantitation of the distribution of Sarl revealed that the car- 
rier vesicles present in the transitional region were enriched 
approximately fourfold compared to the cis-Golgi cisternae 
and nearly 20-fold enriched compared to either the bulk of 
the ER or the trans-Golgi cisternae (Table II). The density 
on the trans-Golgi face was similar to that found over the nu- 
cleus (Table H), while the density over the bulk of the ER 
was approximately twofold greater than this level. Assuming 
the concentration of immunogold particles detected over the 
nucleus and the trans-Golgi compartments represents non- 
specific background,  then  the  enrichment of Sarl  in  the 
pre-Golgi  vesicular  carriers  is  exceptionally high  (up  to 
40-50-fold). These results are, in part, consistent with in- 
direct immunofluorescence studies in yeast where Sarlp was 
detected in a diffuse, perinuclear, and reticular localization 
which overlapped with Kar2p and Sec62p, both resident ER 
proteins (Nishikawa and Nakano, 1991). Interestingly, Sarlp 
could also be detected in punctate structures in yeast which 
did not overlap with either ER or Golgi markers (Nishikawa 
and Nakano,  1991).  These may represent pre-Golgi inter- 
mediates. 
Sarla(T39N) Inhibits Export of VSV-G 
from the ER In Vivo 
To identify the potential role of Sarla in the regulation of ER 
to Golgi traffic in mammalian cells, mutations were gener- 
ated with motifs involved in guanine nucleotide interactions. 
Extensive mutational and structural analysis of Ras and Rab 
proteins have defined the essential amino acid residues in 
these motifs which are involved in the binding and hydrolysis 
of GTP (reviewed in Barbacid, 1987;  Bourne et al.,  1991). 
Two mutations were initially generated. These mutations are 
located in  two  of the four conserved guanine nucleotide- 
binding regions (Table III). The first mutant,  Sarla(N134I) 
contains a single point mutation (N134I) in the NKxD motif 
(residues 116-119  in p21 "-r~) which is essential for stabili- 
zation of the nucleotide-binding pocket (Pai  et al.,  1989, 
1990). The equivalent substitution in p21H-*~ (Nll6I) has a 
dominant negative phenotype and triggers oncogenic trans- 
formation.  This  mutant  protein  is  defective  in  guanine 
nucleotide binding and has an exceptionally high exchange 
rate (Walter et al., 1986). In yeast, the corresponding muta- 
tions in the yptl or sec4 alleles (involved in ER to Golgi and 
post-Golgi transport, respectively) result in dominant lethal 
phenotypes which correlate with  severe secretory defects 
(Schmitt et al., 1986, 1988; Walworth et al., 1989). In mam- 
malian cells, an equivalent Rablb(N121I) mutant inhibits ER 
to Golgi transport resulting in the accumulation of VSV-G 
in pre-Golgi intermediates in vivo (Tisdale et al.,  1992) and 
in vitro (Pind et al.,  1994). 
The second mutant, Sarla(T39N) carries a substitution in 
the GxxxxGKS/T domain (residues 10-17 in p21H-~) which 
Table II.  Sarl lmmunogold Labeling of Transitional 
Area, ER and Golgi of Pancreatic 13-cells* 
Number of gold particles 
per t~m  2 +  SEM 
Nucleus  8  +  3  *n  =  8 
ER  19  -t-  5  n  =  8 
Transitional area§  123 ± 23  n  =  7 
Transitional vesicles of transitional area  388 ±  72  n  =  7 
Cis Golgi  108 +  23  n  =  8 
Trans Golgi  13 +  3  n =  8 
* Quantitation of the  immunogold-labeled sarl  on  compartments  was  per- 
formed as described in Materials and Methods. 
)  n  =  number of pictures evaluated. 
§ 98  +  2 %  of the particles was associated with the vesicles. 
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bution  of Sarl  in  pancreatic 
/3-cells. (A) Field of a pancre- 
atic  insulin  cell  comprising 
transitional elements (TE) of 
the ER,  the proximal part of 
the  Golgi complex  (G)  and 
abundant intervening vesicles. 
Sarl immunogold particles are 
preferentially associated with 
transitional elements and prox- 
imal  Golgi  cistemae.  The 
transitional  region  contains 
clusters  c~  immunolabeled vesi- 
cles,  together  with  clusters  of 
unlabeled vesicles.  (B) Pan- 
creatic  insulin  cell  showing a 
bell-shaped  transitional cis- 
tcrna (TE),  transfer  vesicles 
and the Golgi complex (G). 
Sarl immunolabeling is  asso- 
ciated with  the  transitional 
cisterna and vesicles, and the 
proximal Golgi cisternae fac- 
ing  the  transitional  region. 
The  trans-Golgi  cisterna  is 
identified by a condensing in- 
sulin secretory vesicle (aster- 
isk). It has a low level of Sarl 
labeling. The inset details Sarl- 
immunolabeled  transitional 
elements  (TE)  and  transfer 
vesicles. See the quantitative 
evaluation of immunolabeling 
in Table 1I.  Bars:  (A and B) 
0.25 #m; (B inset) 0.21  #m. 
The Journal of Cell Biology,  Volume 125, 1994  56 Table IlL  Comparison of GTP-binding Domains  of Sarl  to Other Members  of the ras Superfamily 
H-ras (human) 
rabl (human) 
ARFI (human) 
SARI (S. cerevisiae) 
SARI (S.  pombe) 
SARI (A. thaliana) 
Sarlb (Chinese  hamster) 
Sarla (Chinese  hamster) 
5  53  112 
NH2 ....  KLVVVGAGGVGKS  .....  LDILDTAGQE .....  VLVGNKCD  ....  COOH 
NH2  ....  KLLLIGDSGVGKS  .....  IQIWDTAGQE  .....  LLVGNKCD  ....  COOH 
NH2  ....  RILMVGLGAAGKT  .....  FTVWDVGGQD  .....  LVFANKQD  ....  COOH 
NH2  ....  KLLFLGLDNAGKT  .....  FTTFDLGGHI  .....  VILGNKID  ....  COOH 
NH2  ....  KMLFLGLDNAGKT  .....  FTTFDLGGHQ  .....  LILGNKID  ....  COOH 
NH2  ....  KILFLGLDNAGKT  .....  FKAFDLGGHQ  .....  LILGNKID  ....  COOH 
NH2  ....  KLVFLGLDNAGKT  .....  FTTFDLGGHE  .....  LILGNKID  ....  COOH 
NH2  ....  KLVFLGLDNAGKT  .....  FTTFDLGGHI  .....  LILGNKID  ....  COOH 
Phospho~l-  Phospho~l-  Guanine ring 
binding site  binding site  con~  site 
The amino acid sequences of sarl-related  proteins, which make up GTP-binding  domain, are compared  t~ H-ras and other members  of the ras superfamily.  The 
numbering is that of H-ras. Mutations used in this study which alter GTP-binding  for ras are indicated by the asterisk. 
is  involved  in  phosphate  binding  and  Mg  2+  coordination 
(Pal et al.,  1989,  1990). It is analogous, in principle, to the 
p21"-~(S17N)  mutant,  which  is  restricted  to  the  inactive 
(GDP-bound)  conformation and  inhibits  cell  proliferation 
(Feig  and  Cooper,  1988;  Farnsworth  et  al.,  1991).  The 
equivalent mutation in Rablb (Rablb[S22N]), is a potent in- 
hibitor of both ER to Golgi and intra-Golgi transport in vivo 
(Tisdale  et al.,  1992)  and  in  vitro  (Davidson  and  Balch, 
1993; Nuoffer et al.,  1994).  Competition experiments were 
performed to compare the relative affinities of the wild-type 
Sarla and the Sarla(T39N) mutant for GDP and GTP. The 
recombinant  proteins  were  incubated  with  [3H]-GDP  (1 
/zM)  in the presence of Mg  2+ (1  raM) and increasing con- 
centrations of unlabeled GDP (Fig. 6, open symbols) or GTP 
(Fig. 6, closed symbols). As expected, in the case of both the 
wild-type  protein  or  mutant  proteins,  supplementing  the 
100, 
80 
j. oo 
a,m 
°'6  40 
10-9  10-8 10-7 I0-6  10-5  10-4  10-3 
GDP  or  GTP  (M) 
Figure 6. The Sarla(T39N)  mutant  has  a  reduced  affinity  for  GTP. 
The wild-type  (t~,  m) and mutant (o, o) proteins  were incubated 
for I  h with [3H]-GDP in  the  presence of  0.1% Triton  X-100 and 
I  mM  MgCI2 and the  indicated  concentrations  of  unlabeled GDP 
(o, n) or  GTP (o, m). Exchange reactions  were  performed by in- 
cubating  0.5 #g (20 pmol) of  recombinant  protein  at  320C with I 
#M  t~H]-GDP  (~5,000  cpm/pmol),  50 mM  Hepes-KOH  (pH 
8.0),  0.1% Triton  X-100, l  mM  MgCI2, I  mM  DTT, and  0.1  mg/rnl 
BSA.  Bound  [3H]-GDP  was quantitated  by liquid scintillation 
counting following  capture  of  the  proteins  on nitrocellulose  mem- 
branes as  described  previously  (Nuolfer  ct  al.,  1994).  The results 
are  expressed  as  the  percentage  of  the  amount of  [3H]-GDP bound 
in  the absence of  additional  nucleotide. 
reaction with  "01 #M  GDP was  sufficient to reduce  pH]- 
GDP binding by ,050% (Fig. 6, open symbols). However, an 
excess of GTP was necessary for half-maximal inhibition of 
[3H]-GDP binding  for the  wild-type  and  mutant proteins 
(Fig. closed symbols),  suggesting that both proteins have a 
higher affinity for GDP than GTP.  Moreover, an "010-fold 
higher concentration of GTP was required for half-maximal 
inhibition of pH]-GDP binding to the Sarla(T39N) mutant 
that wild-type Sarla (Fig. 6, closed symbols), indicating that 
the predominant consequence of the T39N substitution with 
respect to guanine nucleotide binding is to reduce the affinity 
of the protein for GTP without altering its affinity for GDP. 
To test if mutated forms of Sarl  inhibit ER to the Golgi 
transport in intact mammalian ceils, a transient expression 
system was employed in which HeLa cells infected with vac- 
cinia recombinant virus (vTF7-3) expressing "1"7 polymerase 
were cotransfected with a wild-type or mutant Sarla plasmid 
DNA and a plasmid encoding for VSV-G under control of the 
Figure 7. Sarla(T39N) ("GDP") potently inhibits ER to Golgi trans- 
port in vivo. Transient expression of wild-type VSV-G in combina- 
tion  with  Sarla  wild-type  (B) or mutant proteins  (C and D) in 
vaccinia-infected Hela ceils was performed as described (Tisdale et 
al., 1992). The mount of VSV-G remaining in the endo H-sensi- 
tive ER form (S), the amount processed to the cis/medial-Golgi in- 
termediate endo H-resistant forms (RI) or the amount processed 
to the complex, sialic acid containing form (Rr) in terminal Golgi 
compartments was determined as described  (Plutner et al.,  1992; 
Tisdale et al.,  1992; Davidson and Balch,  1993). The control (A) 
contained only the VSV-G expression construct. 
Kuge et  al.  Sat1  Regulation  of  ER Export  57 T7 promoter (Tisdale et al.,  1992). Briefly, 4 h post-infec- 
tion/transfection cells were pulsed with 35S-Met for 10 min. 
The pulse was followed by a chase for 90 min in the presence 
of  unlabeled Met. The extent of transport of VSV-G from the 
ER to different Golgi compartments was quantitated by fol- 
lowing the processing of VSV-G N-linked oligosaccharides 
acquired in the ER to various Golgi forms using SDS-PAGE 
(Tisdale et al., 1992). In HeLa ceils, three distinct processed 
forms of VSV-G can be detected after increasing time of in- 
cubation during the chase period (Plutner et al.,  1992; Tis- 
dale et al., 1992; Davidson and Balch, 1993). One form cor- 
responds to the endo H-sensitive form found in the ER and 
pre-Golgi intermediates (S in Fig. 7). A second form appears 
coincident with  the transport of VSV-G  to  the  early cis/ 
medial-Golgi compartments which generates an early endo 
H-resistant form lacking terminal Gal and sialic acid resi- 
dues (R1 in Fig.  7).  Subsequently, VSV-G is processed in 
the  terminal  (trans) Golgi  compartments  to  the  complex 
forms containing Gal and terminal sialic acid (Rr in Fig. 7). 
VSV-G  was  first cotransfected with the Sarla wild-type 
plasmid. As shown in Fig. 7, the extent of VSV-G detected 
in the cis/medial  R~ form (17%) or the trans/TGN Rr form 
(60%) was identical to the control lacking the Sarla wild- 
type plasmid (Fig. 7 b). The level of expression of the Sarla 
wild-type and mutant proteins was generally two- to fourfold 
higher than the level of the endogenous Sarl pool based on 
Western blotting (data not shown). Thus, overexpression of 
wild-type Sarla neither inhibited nor stimulated transport. In 
contrast, overexpression of the Sarla(T39N) "GDP-bound" 
form strongly inhibited transport (Fig. 7 c). In this case, less 
than 20% could be detected in the Rr terminally processed 
form, with over 70 % retained in pre-Golgi endo H-sensitive 
forms.  A  weak,  but  reproducible inhibition was  also ob- 
served with Sarla(N134I) (Fig. 7 d). In a typical experiment, 
32% of the VSV-G remained in the endo H-sensitive S form 
as Compared to the control in which generally 20-22 % re- 
mained in the unprocessed form after a 90-min chase. The 
inability of this mutant to strongly inhibit transport may re- 
flect its instability in vivo (see Discussion). 
To  determine  the  morphological  site  of inhibition  by 
Sarla(T39N) in vivo, the distribution of VSV-G was exam- 
ined using indirect immunofluorescence. In this case, HeLa 
cells  were  transfected with  a  plasmid  expressing  a  ther- 
moreversible form of VSV-G (tsO45) which fails to exit the 
ER when cells are incubated at the restrictive temperature 
(39.5°C)  (Lafay, 1974) (Fig.  8 A), but is efficiently trans- 
ported to the Golgi when ceils are subsequently shifted to 
the permissive temperature (32°C) (Fig. 8 B, arrow). When 
cells were cotransfected with tsO45 VSV-G  and wild-type 
Sarla, transport to the Golgi was normal (Fig. 8 B), consis- 
tent with the inability of the wild-type protein to prevent 
oligosaccharide processing during transient expression. In 
contrast, overexpression of Sarla(T39N) by two- to fourfold 
potently inhibited export from the ER (Fig. 8 C). Quantita- 
tively,  >80-90%  of the  transfected cells  failed to  export 
VSV-G from the ER in the presence of Sarla(T39N).  This 
result supports the interpretation that the role of mammalian 
Sarla, like that observed in yeast, is to regulate export from 
the ER. 
Sarla Is Required  for ER to Golgi Transport In Vitro 
To examine the biochemical role of Sail in transport, we uti- 
lized an assay which efficiently  reconstitutes ER to Golgi and 
intra-Golgi transport  in  semi-intact cells  (Beckers et al., 
1987; Baker et al.,  1988; Schwaninger et al.,  1991; Plutner 
et al., 1992; Davidson and Balch, 1993). The assay was sup- 
plemented  with  UDP-GlcNAc  to  promote  processing  of 
VSV-G  to  the  R~  endo  H-resistant  form  (Davidson  and 
Balch,  1993).  Addition  of affinity-purified antibody  was 
Figure 8. Transient expression of Sarla(T39N) in vivo inhibits the export of VSV-G from the ER. Vaccinia-infected  HeLa cells were trans- 
fected with a plasmid expressing the temperature-sensitive (tsO45) form of VSV-G for 4 h at 39.5°C. 4 h after transfection, cells were 
either retained at the restrictive temperature (39.5°C) (A) or shifted to the permissive temperature (32°C) and incubated for 2 h in the 
presence of wild-type Sarla (B) or Sarla(T39N) (C) as described previously (Tisdale et al.,  1992). Cells were fixed, permeabilized, and 
the distribution of tsO45 VSV-G determined as described previously (Plutner et al.,  1992). In (B, arrow), VSV-G exactly overlaps with 
Lens culinaris lectin which binds principally to terminal N-acetylglucosamine, a marker for cis/medial compartments of the Golgi. 
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not intra-Golgi transport  in vitro.  Semi-intact cells  and cytosol 
were preincubated for 60 min on ice in the presence of  the indicated 
concentration of affinity purified antibody specific  for Sarl  (open 
circles).  In the closed circles, Sarla wild-type protein was added 
at a fivefold molar excess during preincubation on ice. Cells were 
subsequently  transferred  to 32°C, and incubated  for 75 min in the 
presence of  ATP and UDP-GIcNAc  as described previously (David- 
son and Balch,  1993).  The amount VSV-G processed to the endo 
H-resistant  fR  O form was  determined as described in Materials 
and Methods.  (Inset) Isolated Golgi stacks  were incubated  in the 
presence of preimmtme IgG (a) or 15/zg of Sarl specific antibody 
(b)  as described in Materials  and Methods.  The extent  of [3H]- 
GIcNAc incorporation is expressed as % of the control lacking ad- 
ditional  Sarla protein. 
found to inhibit ER to Golgi transport by >90% (Fig. 8, open 
circles). Inhibition was specific since incubation of the anti- 
body in the presence of recombinant Sarla wild-type protein 
at  molar  excess  neutralized  inhibition  (Fig.  9,  closed cir- 
cles). Since the antibody inhibition may result from aggrega- 
tion of Sarla in the membrane, F,b fragments were prepared 
and also found to potently inhibit transport (data not shown). 
In contrast, when the effects of the antibody were tested on 
an assay which reconstitutes the transport of  VSV-G between 
isolated Golgi stacks, no significant inhibition was observed 
(Fig. 9, inset). These results provide evidence that Sarl may 
be a GTPase required for export of protein from the ER, but 
not for transport  through subsequent  compartments  of the 
Golgi complex. 
Given the striking effects of expression of Sarla(T39N) on 
ER to Golgi transport  in vivo (Figs.  7  and 8),  the effect of 
Figure 10. Sarla T39N inhibits an early step in ER to Golgi trans- 
port in vitro.  Semi-intact cells were incubated at 32°C in the pres- 
ence of UDP-GIcNAc as described in Materials and Methods.  (A) 
The amount of VSV-G protein processed to the endo H-resistant 
R1 form in the presence (ctl) or absence of cytosol (-cyt) (a), or 
(b) in the presence of  cytosol supplemented  with increasing concen- 
trations of  the Sarla wild-type or the Sarla(T39N) recombinant pro- 
teins.  (B) Semi-intact cells were incubated for increasing time (A0 
at 32"C prior to transfer to ice to terminate transport (open circles), 
or supplemented  with 5 ttg Sarla(T39N) for 10 min on ice prior to 
reincubation at 32°C for a total time of 90 min (closed circles). In 
the open squares,  cells were mock treated by the addition of buffer 
lacking Sarla(T39N).  (B, inset) Semi-intact cells were incubated in 
the presence of either 5 ttg Sarla wild-type or Sarla(T39N) for 75 
min. The amount of VSV-G processed to either the RI or Rr forms 
in the presence of UDP-GIcNAc, UDP-Gal and CMP-SA was deter- 
mined as described (Davidson and Balch, 1993). (C) Isolated Golgi 
stacks were incubated  in the presence of increasing  concentration 
of Sarla wild-type or Sarla(T39N) as described in Materials  and 
Methods.  The extent  of [3H]-GIcNAc incorporated is  expressed 
as the % of the control level of transport lacking additional  Sarla 
protein. 
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VSV-G transport in vitro was examined. As shown in Fig. 10 
A,  addition of increasing concentrations Sarla(T39N)  in- 
hibited transport in vitro by nearly 95 %. Transport hras in- 
hibited by 50 % in the presence of ~  2.5 ~g Sarla(T39N) with 
maximal inhibition above 5 tzg. No inhibition was detected 
in the presence of an equivalent concentration of the wild- 
type protein (Fig. 10 A). The level of  inhibition by the mutant 
was found to vary between different preparations of recom- 
binant protein. The most active preparation inhibited trans- 
port with an IC5o of 0.5  Izg with maximal inhibition in the 
presence of 1.5 #g. 
Transport of  VSV-G from the ER to the cis-Golgi compart- 
ment generally has a  15-20-min lag  period during which 
time 40-80-nm carrier vesicles bud and target to the cis face 
of the Golgi stack (Plutner et al., 1992; Balch et al., 1994). 
To determine whether Sarla was required for an early step 
reflecting vesicle budding or a later step involved in targeting 
or fusion, the T39N mutant protein was added at increasing 
time after initiation of transport.  As  shown in Fig.  10 B, 
transport became rapidly (within 5-10 min) insensitive to the 
addition of Sarla(T39N) to the assay. For example, after only 
10 rain of incubation in vitro, a time-point in which Golgi 
processed forms of VSV-G cannot be detected, >60% of the 
total VSV-G transported in the control lacking Sarla(T39N) 
was processed to the endo H-resistant R, form in the pres- 
ence of the mutant (Fig.  10 B). Therefore, Sarla is clearly 
recruited at a very early step in transport. 
Is Sarl  required only for export of protein from the ER, 
or, is it required also for vesicle formation from Golgi com- 
partments? To address this question directly semi-intact cells 
were incubated in vitro in the presence of the sugar nucleo- 
tide precursors UDP-GlcNAc, UDP-Gal,  and CMP-SA to 
promote the  processing  of VSV-G  to  the  terminally gly- 
cosylated  (RT) form  during  transport  to  the  trans-Golgi 
compartment (Davidson and Balch, 1993). As shown in Fig. 
10 B (inset), in the presence of wild-type Sarla, VSV-G was 
efficiently processed to the R~  (22%) and R7 (50%) forms 
after a 90-rain incubation, similar to control values obtained 
in the absence of exogenous Sarla.  In contrast, in the pres- 
ence of the T39N mutant the small proportion of VSV-G 
which was exported from the ER (18 % of  total) was quantita- 
tively chased to  the  mature,  RT  form with  less  than  5% 
found in the Rt form, suggesting  that the mutant was inca- 
pable of blocking intra-Golgi transport. 
To pursue the above important observation, we examined 
the effect of the addition of the Sarl(T39N) mutant after in- 
creasing times of incubation. As a control, GTP,ySt (a non- 
hydrolyzable analog of GTP which inhibits both ER to Golgi 
and intra-Golgi transport in semi-intact cells [Beckers and 
Balch, 1989; Schwaninger et al., 1992; Davidson and Balch, 
1993]) was added in a parallel set of incubations. In these 
experiments, addition of the reagent was followed by further 
incubation of cells  for a  total time of 120 rain  to  allow 
any VSV-G which had matured past a particular T39N- or 
GTP,yS-sensitive step(s) to be processed in the subsequent 
Golgi compartment(s) (Fig.  11). As illustrated in Fig.  11 A 
and quantitated in Fig.  11, B-D, whereas GTP-yS led to the 
accumulation of VSV-G in the Rt form when added to early 
time points (see Fig. 11 C), addition of Sarla(T39N) consis- 
tently led to maturation of VSV-G to the RT form with little 
accumulation in the R~ form (see Fig.  11, C and D). In each 
Figure 11. Sarl is required only for export from the ER. Incubation 
condRions for transport of VSV-G in vitro were as described in the 
Materials and Methods. (a), (top) Semi-intact cells were incubated 
in the presence of  50 ~tM UDP-GIcNAc,  0.5 mM UDP-Gal, and 100 
~M CMP-sialic acid for increasing time at 32°C prior to transfer 
to ice to terminate transport (time course Tc). (Middle and bottom) 
Cells were supplemented with 25 #M GTP3,S (middle, GTP'),S)  or 
1 Izg Sarla(T39N) (bottom, T39N) at the indicated time, followed 
by incubation at 32°C for a total time of 120 rain. (B-D) Quantita- 
tion of the data shown in a. (Closed squares) Time courses (Tc) for 
the processing of VSV-G to the R1 +RT forms (b), the R~ form (c) 
or the RT form (d).  (Open  circles) The amount (%  of total) of 
VSV-G recovered in the R1 +RT form (b), the R1 form (c) or the RT 
form (d) in the presence of GTP3,S added at the indicated time. 
(Open  triangles)  The extent of VSV-G recovered in the RI +RT 
form (b), the R~ form (c) or the RT form (d) after 120 rain incuba- 
tion in the presence of Sarla(T39N) (1 ~g) added at the indicated 
time.  The amount of R~  recovered in the presence of the T39N 
mutant at later time points (c, open triangles) reflects the residual 
VSV-G which was not transported from the cis/medial-Golgi com- 
partments to the trans-Golgi compartment in the control (c, closed 
squares). The amount of VSV-G processed to either the R1 or RT 
formS waS determined as described in Materials and Methods. 
case,  the  inhibitory  effect  of  the  mutant  (or  GTP~S) 
preceded processing by •5-10  min, consistent with the no- 
tion that both reagents inhibit an early step in vesicle func- 
tion.  Thus,  it  is  evident  that  while  the  general  reagent 
GTP'yS inhibits vesicle formation between multiple com- 
partments, Sat1 is required only for export from the ER. 
The effects of Sarla were also examined using an assay 
which reconstitutes the transport of VSV-G between isolated 
Golgi stacks (Balch et al.,  1984). When Sarla(T39N) was 
added at a  concentration sufficient to inhibit ER to Golgi 
transport by >80% (5 ~tg) (Fig. 10 A) only partial inhibition 
of transport was observed. In this case, inhibition was less 
than 25 % of a control incubation containing an equivalent 
concentration of wild-type Sarla (Fig. 10 C). The latter pro- 
tein also partially inhibited (by *25%) transport. The weak 
inhibition of transport between isolated Golgi stacks by ei- 
ther the wild-type or Sarla(T39N) mutants may reflect non- 
specific effects of the recombinant protein on the assay. Nei- 
ther wild-type nor mutant Sarla were found to have any effect 
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analysis of transport using indirect immunofluorescence were performed as described (Plutner et al.,  1992). (A and B) Distribution of 
VSV-G (A) and Man 1I (B, arrows)  prior to incubation in vitro. Man II is a marker protein for the cis/medial-Golgi compartments in NRK 
cells (Plutner et al., 1992; Velasco et al., 1993). (C and D) Transport of VSV-G in cells incubated for 45 min at 32°C in vitro to pre-Golgi 
intermediates (C, open arrows)  and Golgi compartments (C, VSIZ-G, arrows;  D, Manll, arrows)  in the presence of 5 #g Sarla wild-type 
protein. The structures denoted by the open arrows in C overlap with the distribution of the pre-Golgi marker protein p58 (Saraste and 
Svensson, 1991) (not shown). (E and F) Distribution of VSV-G (E) and Golgi (F,, Manll, arrows) in permeabilized ceils incubated for 
45 rain at 32°C in the presence of  5 #g of Sarla(T39N). Small arrows in (E) denote transport of  VSV-G  to punctate, pre-Golgi intermediates 
which overlap with the distribution of p58 (not shown). 
on the steady state distribution of B-COP on Golgi compart- 
ments (data not shown). 
Sarla(T39N) Specifically Inhibits Budding 
from the ER In Vitro 
To identify the step in transport between the ER and the Golgi 
which requires Sarl, digitonin-permeabilized cells (Plumer et 
al.,  1992) were incubated for 45 min in the presence of the 
mutant protein and the distribution of tsO45 VSV-G was ex- 
amined  using  indirect immunofluorescence. As  shown  in 
Fig.  12, prior to incubation in vitro, VSV-G is restricted to 
the ER (Fig.  12 A). As expected, incubation of cells in the 
presence of the Sarla wild-type protein leads to the efficient 
transport of VSV-G from the ER to pre-Golgi intermediates 
(Fig.  12  C,  open arrows) and compartments of the Golgi 
stack containing the Golgi marker enzyme a-l,2 mannosi- 
dase II (compare Fig. 12, C and D, arrows). In contrast, in- 
cubation in  the presence of the  T39N mutant largely in- 
hibited exit from the ER (Fig. 12 E). Most of  the VSV-G was 
retained  in  a  diffuse ER  staining  pattern,  although  some 
migration of VSV-G to punctate pre-Golgi could be detected 
(Fig.  12 E, small arrows), presumably reflecting the small 
amount of VSV-G able to escape the block at this concentra- 
tion of T39N. Addition of an inhibitory concentration of the 
afffinity-purified  Sarl-specific antibody also completely pre- 
vented export of VSV-G from the ER in vitro (not shown). 
These data are consistent with the results observed in vivo 
(Fig. 7), and suggest that the Sarl GDP-bound mutant rap- 
idly and efficiently competes with the endogenous wild-type 
pool for an effector molecule critical for the generation of 
transport vesicles from the ER. 
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Sarl Is Enriched on ER to Golgi Carrier Vesicles 
in Mammalian Cells 
The localization of Sarl to the transitional region of the ER 
provides one of several lines of evidence that it functions in 
ER to Golgi transport.  Sarla was enriched 20-40-fold on 
putative ER to Golgi carrier vesicles and nearly 10-fold in 
the transitional region relative to its distribution in the bulk 
of the ER membrane. Transitional elements are believed to 
be specialized sites of export of newly synthesized protein 
from the labyrinth of rough Ell (RER), an organelle which 
is  exceptionally  abundant  in  insulin-secreting  pancreatic 
cells. In contrast to Art (Stearns et al., 1990) or Rabl/Ypflp 
(Segev et al., 1988; Plutner et al., 1991; Pind et al., 1994), 
which are abundant on pre-Golgi carrier vesicles and multi- 
ple compartments of the Golgi stack, Sarl was confined to 
the cisternal elements of the proximal face of the Golgi. In 
yeast, Sarlp has been detected using indirect immunofluores- 
cence on perinuclear ER elements which contain Kar2p and 
Sec62p,  and small punctate structures which are likely to be 
pre-Golgi intermediates, but not in Golgi compartments con- 
taining  the  KEX2  gene  product,  a  trans-Golgi  marker 
(Nishikawa and Nakano, 1991). Sarlp has also been detected 
in exaggerated ER structures which accumulate at the re- 
strictive temperature in the presence  of the temperature- 
sensitive secl2 and secl8 alleles, but was not detected in 
Golgi-like compartments which accumulate at the restrictive 
temperature in the presence of either the secl or sec7 mutant 
alleles (Nishikawa and Nakano,  1991). Consistent with the 
distribution of mammalian Sarlp,  a  protein which cross- 
reacts with an antibody specific for the yeast Sarlp-specific 
GAP (Sec23p) has also been localized to the transitional re- 
gion of the ER in insulin-secreting cells (Orci et al., 1991a). 
Two additional lines of evidence support a role for Sarl in 
vesicle budding from the ER. First, a Sarl-specific antibody 
inhibited export, possibly by preventing the assembly of a 
Sarl-regulated coat complex. Second, the T39N mutant was 
a potent inhibitor of transport of VSV-G between the ER and 
the cis-Golgi compartment. While we reported inhibition of 
transport based on the inability of VSV-G to be processed to 
the endo H-resistant R1  form, we have observed identical 
levels of inhibition in the processing of VSV-G to the endo 
D-sensitive, 5 mannose (Mans) containing form in a CHO 
cell line (clone  15B) defective in modification of VSV-G 
NH2-1inked  oligosaccharides  beyond  the  Man5 structure 
(Rowe, T. and W. E. Balch, unpublished observations). This 
processing intermediate immediately precedes the appear- 
ance  of the  R1  form  and  is  a  hallmark  for  delivery  of 
VSV-G protein to the cis-Golgi compartment (Beckers et al., 
1987; Plutner et al.,  1992;  Davidson and Balch, 1993). 
How does the Sarla(T39N)  mutant inhibit export? This 
mutation is equivalent to the S17N substitution in p21 e  .... 
which disrupts the contribution of the hydroxyl group of Set- 
17 to the Mg  2+ ion involved in guanine nucleotide binding 
(Feig and Cooper, 1988; Farnsworth et al., 1991). This abol- 
ishes the high affinity of p21 ~-r~ for GTP producing a GDP- 
bound form.  Improper complexing of Mg  2+ also restricts 
p21R-~ to a conformationally inactive state. The S17N mu- 
tant is believed to interfere with wild-type Ras function in 
vivo by serving as a competitive inhibitor for the nucleotide 
exchange factor (GEF), thereby preventing GDP/GTP ex- 
change on the endogenous wild-type pool and leading to in- 
hibition of cell growth (Farnsworth et al., 1991). The capac- 
ity of the Sarla(T39N)  mutant to efficiently inhibit export 
from the ER suggests that it is rapidly equilibrated with the 
endogenous, functional Sarl pool. Given the altered guanine 
nucleotide binding properties of the Sarla(T39N) mutant, a 
reasonable interpretation at this time is that the T39N mutant 
may compete with the wild-type protein for a Sarla-speeific 
GEE  interfering with the recruitment of Sarl  to the ER 
membrane. This interpretation is consistent with the effects 
of a  temperature-sensitive allele of the Sarlp-specific ex- 
change factor (Secl2p-GEF)  which, in yeast leads to the 
proliferation of ER elements in cells incubated at the restric- 
tive temperature (Novick et al., 1980; Nakano et al., 1988). 
The reduced ability of the Sarlp-GEF in the presence of the 
T39N mutant to support vesicle budding is consistent with 
the proposed role of other GEF's involved in the recruitment 
and activation of Art  (Donaldson et al.,  1992a,b;  Helms 
and  Rothman,  1992;  Daseher  and  Balch,  1994),  Rabl 
(Nuoffer et al.,  1994),  and SEC4 (Moya et al.,  1993).  In 
general, molecules promoting nucleotide exchange may play 
a crucial first step in the recruitment and subsequent activa- 
tion of small GTP-bindlng proteins  involved in vesicular 
transport between compartments of the exocytic and endo- 
cytic pathways. 
The N134I substitution was considerably less potent than 
the T39N mutant in inhibiting ER to Golgi transport. We 
found this surprising given the fact that equivalent mutations 
in Rabla (N124I),  Rablb(N121D,  and Rab2 (N1191I) are po- 
tent trans dominant inhibitors of ER to Golgi transport in 
vivo and in vitro (Tisdale et al.,  1992;  Pind et al.,  1994). 
Rabl mutants allow vesicles to bud from the Ell, but prevent 
their fusion to the cis-Golgi  compartment (Tisdale et al., 
1992; Pind et al., 1994). In yeast, the equivalent yptl or see4 
mutant alleles are dominant lethal with marked secretory 
defects (Schmitt et al., 1986, 1988; Walworth et al., 1989). 
In the case of p21H-~', the Nll6I substitution destabilizes 
the nucleotide-bindlng pocket (Der et al.,  1986;  Feig and 
Cooper,  1988;  John et al.,  1993),  resulting in a  high ex- 
change rate. This altered conformation restricts p21H-r.s to 
the  activated  state,  triggering  oncogenic  transformation 
(Walter et al., 1986). One possible explanation for the inabil- 
ity of Sarla(N134I)  to inhibit transport is that the folding or 
stability of the protein is compromised. Consistent with this 
interpretation, we found that expression of the Sarla(N134I) 
mutant in E.  coli  leads to extensive aggregation.  Unlike 
similar mutations in Rabl (Nuoffer et al., 1994; Pind et al., 
1994),  we have been unable to purify a soluble form of the 
N134I mutant to test its function in vitro. Further analysis 
of this mutant and a mutant restricted to the GTP-form are 
currently under investigation. 
Sarl, a GTPase Specific for Export from the ER 
The striking enrichment of Sarl on transitional carrier vesi- 
cles,  and the  ability of both  Sarl-specific antibodies and 
the T39N mutant to inhibit ER to Golgi, but not intra-Golgi 
transport in semi-intact cells, supports the conclusion that 
Sarl regulates vesicle budding at only one step of the secre- 
tory pathway-export from the ER.  While the biochemical 
evidence for this interpretation is compelling, it is inconsis- 
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(Sarlp-GAP) function was required  for at least two sequen- 
tial steps:  transport  from the ER to the cis-Golgi  compart- 
ment, and between early,  but not late Golgi compartments 
(Graham and Emr, 1991).  At this time there are three possi- 
ble explanations for this apparent contradiction. One possi- 
bility, albeit one which we consider unlikely, is that the com- 
partmental  organization of the early  secretory pathway  in 
yeast is different from that found in mammalian cells. Alter- 
natively,  an interpretation  of the genetic analysis which can- 
not be ruled out is that Sarlp/Sec23p are essential for deliv- 
ery of factor(s) which is subsequently required for transport 
between early, but not late Golgi compartments (Graham and 
Emr,  1991).  Finally,  it remains to be established whether a 
larger Sar gene family exists, similar to that observed for Rab 
and which may contain many more divergent species special- 
ized for individual stages of the exocytic (or endocytic) path- 
way. In this case, Sec23p may serve as a common GAP for 
several of these related GTPases. In any case, the presence 
of Sarlp on the cis-face of the Golgi stack is consistent with 
the possibility that this distribution  represents its site of recy- 
cling for reuse in multiple rounds of transport. 
The requirement for a unique GTPase-regulating  export 
from the ER is intriguing  given recent evidence that export 
of protein from the ER may involve both the sorting and con- 
centration of cargo from resident ER proteins during vesicle 
budding (Mizuno and Singer,  1993;  Balch et al.,  1994).  In 
contrast, transport  between sequential Golgi compartments 
occurs without further concentration  (Orci et al., 1989; Balch 
et al.,  1994).  These observations can be rationalized if the 
transport  machinery governing export from the ER differs, 
at least in part, from that involved in transport between com- 
partments  of the Golgi stack. It is now recognized that coat 
components found on nonclathrin-coated vesicles mediating 
transport  between  Golgi  compartments  (Serafini  et  al., 
1991a,b;  Waters et al., 1991; Taylor et al., 1992; Orci et al., 
1993;  Palmer et al.,  1993) as well as components involved 
in fusion of Golgi carrier vesicles (Wilson et al., 1989; Roth- 
man and Orci,  1992;  S611ner et al., 1993) are also required 
for ER to Golgi transport in mammalian cells (Beckers et al., 
1989; Pepperkok et al., 1993; Peter et al., 1993; Pind et al., 
1994) and in yeast (Kaiser and Schekman, 1990;  Hosobuchi 
et al.,  1992).  One possible role for Sarl may be to provide 
an additional level of regulatory control, perhaps  related to 
the need to sort and concentrate cargo to ensure efficient ex- 
port from the bulk of the ER (Balch et al.,  1994). 
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